Flen Health Chooses AGC Biologics to Manufacture Recombinant Enzymes for Next-Generation Wound Treatment

Heidelberg site to lead GMP development of lactoperoxidase and glucose oxidase for Phase II clinical trials HEIDELBERG, Germany, September 24, 2026 -- Belgian biopharmaceutical company Flen Health has selected AGC Biologics as their CDMO partner to provide process development, scale-up, and GMP manufacturing services for a new and improved wound and skin healing product. Manufacturing Services to Support Regulatory Submissions, Clinical Trials With cell line development from myBIOS complete, AGC Biologics' Heidelberg, Germany facility will partner for the next stage of development and clinical-scale manufacturing of two recombinant proteins, lactoperoxidase and glucose oxidase, the enzymatic components at the core of the wound treatment’s novel mechanism of action. Following the technology transfer, AGC Biologics will conduct microbial manufacturing at 100-liter and 1,000-liter scale using the Pichia pastoris expression system, in support of Flen Health's planned Investigational New Drug submission and Phase II clinical trials. A Novel Combination Product Flaminal® has been used clinically for 25 years in European markets as a topical enzyme-alginate gel for difficult-to-heal wounds. Classified as a medical device, the therapeutic approach combines a recombinant enzyme system within an alginate matrix to accelerate wound healing. Flen Health is now advancing an improved, recombinant version of the product as part of its strategic entry into the U.S. market, which has seen limited changes to the chronic and acute wound care sector in recent years. Addressing a Serious Diabetes Complication Diabetic foot ulcers remain one of the most undertreated complications in chronic wound care, affecting up to 25% of diabetic patients in their lifetime with an annual cost of $13 billion to the US healthcare system. Diabetic foot ulcers are the leading cause of lower extremity amputations among people with diabetes, accounting for about 85% of such procedures. Globally, 10.2% of the population are living with diabetes and the prevalence of the disease continues to rise, increasing the risk of non healing foot ulcers and further straining healthcare systems. Effective wound repair in DFUs is challenged by disrupted cell communication, impaired inflammatory responses, and a hostile healing environment. The Next Chapter for Enzyme-based Wound Therapies While Flen Health’s Phase 0 human study will utilize current food-grade enzyme formulations, the strategic transition to AGC Biologics’ pharma-grade recombinant enzymes will occur ahead of Phase II clinical trials, applying deep expertise in a world class GMP facility in preparation for U.S. regulatory submissions. "Patients with diabetic foot ulcers need better treatment options,” said Georges Sollie, CEO of Flen Health. “By combining our novel recombinant enzyme platform with AGC Biologics' manufacturing expertise, we are accelerating the development of a promising new therapeutic approach." "As we now advance into full GMP development and manufacturing, we are building on a successful feasibility program we initiated with Flen Health in July 2025. That is exactly the pattern we pride ourselves on, building trust and mutual collaboration with our customers,” said Dieter Kramer, Managing Director, AGC Biologics Heidelberg. “We're thankful Flen Health has entrusted us with this next chapter." In addition to the Heidelberg location, AGC Biologics’ global microbial manufacturing network includes facilities in Copenhagen, Denmark; Seattle, USA; and China, Japan

Flen Health Chooses AGC Biologics to Manufacture Recombinant Enzymes for Next-Generation Wound Treatment

Gerelateerde producten

External Links